ACSL1

Across TCGA pan-cancer cohorts, ACSL1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACSL1 data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ACSL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACSL1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

GBM, LUAD, and HNSC are the cancer types where ACSL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.336	0.725	<.001	16	view →
LUAD	OS	Quartile	III,IV	0.925	0.346	.009	10	view →
HNSC	OS	Median	All	1.000	0.484	.038	6	view →
PDAC	OS	Tertile	III,IV	0.438	1.000	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACSL1–GBM (OS)

Open the GBM breakdown →